• Contact
Augurex
  • Solutions
    • Solution Portfolio
    • Rheumatoid Arthritis
    • Axial Spondyloarthritis
    • Find a Test
  • Science
  • About
    • Company
    • Leadership
  • News
  • Careers
Select Page
Featured in SAA’s eSUN Newsletter: Advancing AxSpA Diagnosis with Anti-14-3-3eta Multiplex

Featured in SAA’s eSUN Newsletter: Advancing AxSpA Diagnosis with Anti-14-3-3eta Multiplex

by Simran Chahal | Jan 27, 2025 | Health, News

Vancouver, Canada – January 27, 2025 – Delays in diagnosing axial spondyloarthritis (axSpA) have been a persistent challenge, with many patients waiting 7 to 10 years for an accurate diagnosis. These delays can lead to missed opportunities for early treatment and a...
Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management

Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management

by Simran Chahal | Nov 15, 2024 | Business, Health, News

Quest to introduce lab-developed test based on Augurex 14-3-3η (eta) biomarker to U.S. physicians later this month   Vancouver, Canada – November 15, 2024 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it...
Augurex and New Day Diagnostics Announce Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents; Enabling a First-In-Class Diagnostic Test for Axial Spondyloarthritis

Augurex and New Day Diagnostics Announce Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents; Enabling a First-In-Class Diagnostic Test for Axial Spondyloarthritis

by Simran Chahal | Nov 13, 2024 | Business, Health, News

Augurex launches Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA) by New Day Diagnostics. The new laboratory developed test, which uses Anti-14-3-3eta...
Augurex to Present Axial Spondyloarthritis Data and Exhibit at ACR Convergence 2024 in Washington, DC

Augurex to Present Axial Spondyloarthritis Data and Exhibit at ACR Convergence 2024 in Washington, DC

by Simran Chahal | Nov 7, 2024 | Events, Health

Augurex will present new research on 14-3-3η auto-antibodies as a diagnostic marker for axial spondyloarthritis. Augurex will be exhibiting at booth #2540, showcasing its innovative diagnostic for rheumatoid arthritis and newly launched first-in-class diagnostic test...
Augurex Announces Agreement with ARUP Laboratories to Expand Access to Advanced Rheumatoid Arthritis Diagnosis with the Launch of 14-3-3η (eta) Test

Augurex Announces Agreement with ARUP Laboratories to Expand Access to Advanced Rheumatoid Arthritis Diagnosis with the Launch of 14-3-3η (eta) Test

by Simran Chahal | Oct 21, 2024 | Business, Health, News

Augurex Life Sciences Corp. announces the launch of the 14-3-3η test by ARUP Laboratories, enhancing the early diagnosis and management of RA.The collaboration between Augurex and ARUP Laboratories highlights a mutual dedication to improving patient outcomes and...
Page 1 of 1012345…10…»Last »
©2024 Augurex Life Sciences. All Rights Reserved. Website by Vanooms Media Inc.